LSD, a laboratory-made psychedelic drug, is tested for persistent anxiety and depression; some take tiny repeated doses hoping for better mood and brain health. One or two supervised full-dose sessions brought lasting anxiety relief in repeated trials; depression evidence is partly mixed. Tiny doses showed no lasting benefit over placebo in healthy adults. Main risks are temporary: frightening experiences, nausea, raised blood pressure; lithium and illicit products add avoidable harm. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Blood pressure | Below 120/80 mmHg | Safety check: high values defer or stop dosing |
| Resting heart rate | 60–100 beats/min | Safety check: a fast heart rate defers dosing |
| CYP2D6 genotype | No established target; record metabolizer status as a personal baseline | Safety check: poor metabolizers warrant a lower dose |
| Echocardiogram (heart valve structure) | No established target; track change from the individual's own baseline | Safety check: new valve thickening stops repeated dosing |
| GAD-7 anxiety score | 0–4, minimal anxiety | Tracks anxiety response |
| PHQ-9 depression score | 0–4, minimal depression | Tracks depression response |
| Pregnancy test (urine hCG) | Negative | Safety check: positive result excludes dosing |
| Electrocardiogram (if cardiac risk factors exist) | Not specified in the ER | Baseline eligibility check |
Cadence: Blood pressure and heart rate before dosing and hourly during full-dose sessions until effects resolve (about 6–12 hours); questionnaires at 1 week, 4 weeks and 12 weeks after a session, then every 3 months if further sessions are considered; for microdosing, questionnaires every 4 weeks and an echocardiogram every 6–12 months while dosing continues.